Analytical Data
-
基因名
VEGF206
-
简介
Vascular Endothelial Growth Factor A (VEGF-A) is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF206 Protein, Human (His) is the recombinant human-derived VEGF206 protein, expressed by E. coli, with N-6*His labeled tag.
- Application
-
别名
VEGFA; VEGFVascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF
-
种属
Human
-
表达系统
E. coli
-
标签
N-6*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P15692-1
-
表达区间
A27-R232
-
氨基酸序列
APMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPGPHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR
-
蛋白长度
Partial
-
分子量
30.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
VEGF206 is a recombinant protein that plays a crucial role in the field of therapeutic angiogenesis and tumor biology. Vascular Endothelial Growth Factor (VEGF) is a key regulator of blood vessel formation, and its various isoforms are known to have distinct biological activities. VEGF206, a specific splice variant of the VEGF gene, has garnered attention due to its potential implications in both normal physiological processes and pathological conditions, including cancer. Research suggests that VEGF206 may exhibit unique properties that influence endothelial cell function, permeability, and survival, thus affecting tumor growth and the progression of various diseases. Understanding the expression patterns and functional roles of VEGF206 can shed light on its contributions to tumor microenvironments and may offer insights into novel therapeutic strategies aimed at modulating angiogenesis. Given the complexity of the VEGF signaling pathway, elucidating the mechanisms by which VEGF206 operates is critical for developing targeted interventions, such as biologics or small molecules, that can mitigate aberrant angiogenesis in cancer and other vascular-related disorders. Additionally, the study of VEGF206 may lead to advancements in tissue engineering and regenerative medicine, making it a significant focus of ongoing research aimed at harnessing the therapeutic potential of this protein in clinical applications.
